MapLight Therapeutics director proposes $13.4K sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Robert Malenka, a director of MapLight Therapeutics, Inc. (MPLT), gave notice of a proposed sale of 736 common shares, with an aggregate market value of $13,354.72 and an approximate sale date of February 24, 2026. He acquired 736 shares on January 23, 2026 through restricted stock vesting under a registered plan.
The notice also lists prior common-share sales by Malenka dated January 28 through February 23, 2026, with individual amounts and gross proceeds.
Key Figures
Key Terms
Restricted stock vesting financial
registered plan regulatory
Aggregate Market Value financial
Gross Proceeds financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.